Immunocore inks deal on gamma delta (γδ) TCR ImmTAC for solid tumors

Shares of UK-based biotech Immunocore Holdings (Nasdaq: IMCR) edged up 2.2% to $61.29 pre-market, as the company announced a collaboration with Netherlands-based Gadeta on the first γδ ImmTAC for solid tumors, including colorectal cancer.

“Immunocore pioneered TCR therapy with the launch of KIMMTRAK and we continue to push the edge of TCR science, including researching non-HLA restricted TCR therapies, both internally and through collaborations that complement our platform,” said David Berman, head of research and development of Immunocore, adding: “We are very pleased to collaborate with Gadeta to combine their expertise in gamma delta TCRs with our scientific, development, and commercialization capabilities to deliver new TCR therapies.”

Terms of the accord